us/
292 pages · Updated August 3, 2026
Pages
- Pascal Haubert | Boehringer Ingelheim US
- Animal health partnering in oral health | Boehringer Ingelheim US
- Summer Internship Program | Boehringer Ingelheim US
- Brigitte Fuhr | Boehringer Ingelheim US
- Benefits & Rewards | Boehringer Ingelheim US
- Boehringer Ingelheim Cares Foundation | Boehringer Ingelheim US
- Christian Betz | Boehringer Ingelheim US
- Human Health Partnering Contact Form | Boehringer Ingelheim US
- USA | Boehringer Ingelheim US
- Shape the future of rheumatology | Boehringer Ingelheim US
- Meet our Team | Boehringer Ingelheim US
- Patricia Rangel | Boehringer Ingelheim Careers | Boehringer Ingelheim US
- Simon Heinrich | Boehringer Ingelheim US
- Japan | Boehringer Ingelheim US
- The Work That You Do | Meaningful Careers at Boehringer | Boehringer Ingelheim US
- Thorsten von Goessel | Boehringer Ingelheim US
- Clinical trials deliver medical breakthroughs – but how do they happen? | Boehringer Ingelheim US
- Dubai | Boehringer Ingelheim US
- Christiane Wijsen | Boehringer Ingelheim US
- Simon Manyara | Boehringer Ingelheim US
- Netherlands | Boehringer Ingelheim US
- When patients share their stories, our purpose comes to life | Boehringer Ingelheim US
- Germany | Boehringer Ingelheim US
- Mexico | Boehringer Ingelheim US
- France | Boehringer Ingelheim US
- Singapore | Boehringer Ingelheim US
- Austria | Boehringer Ingelheim US
- Brazil | Boehringer Ingelheim US
- Hannah Bussmann | Boehringer Ingelheim US
- Argentina | Boehringer Ingelheim US
- Emerging Talent | Boehringer Ingelheim US
- Boehringer Ingelheim Medicine PharmD & PhD Post-Doctoral Fellowship | Boehringer Ingelheim US
- Nelli Milosch | Boehringer Ingelheim US
- Corporate Affairs | Boehringer Ingelheim US
- People, Finance & Organization | Boehringer Ingelheim US
- Research & Development | Boehringer Ingelheim US
- Legal & Compliance | Boehringer Ingelheim US
- Bok Oh | Boehringer Ingelheim US
- Dirk Esser | Boehringer Ingelheim US
- Galym Zhunisbekov | Boehringer Ingelheim US
- Quality | Boehringer Ingelheim US
- Data Careers | Boehringer Ingelheim US
- Medicine & Regulatory Video | Boehringer Ingelheim US
- Dominik Huber | Boehringer Ingelheim US
- Maria Wlaschitz | Boehringer Ingelheim US
- Alexander Guntur | Boehringer Ingelheim US
- Benefits and wellbeing | Boehringer Ingelheim US
- Jan-Erik Schafer | Boehringer Ingelheim US
- Albert Paul | Boehringer Ingelheim Careers | Boehringer Ingelheim US
- Learning and growth | Boehringer Ingelheim US
- Compensation and rewards | Boehringer Ingelheim US
- Michael Schmelmer | Boehringer Ingelheim US
- Dr Armin Wiesler | Boehringer Ingelheim US
- Frank Hübler | Boehringer Ingelheim US
- Shashank Deshpande | Boehringer Ingelheim US
- Expanded Access Programs | Boehringer Ingelheim US
- Cats | Boehringer Ingelheim US
- Harsha Deshmukh | Boehringer Ingelheim US
- Dogs | Boehringer Ingelheim US
- Patient Safety & Pharmacovigilance at Boehringer Ingelheim | Boehringer Ingelheim US
- Animals We Support | Boehringer Ingelheim US
- Cancer | Boehringer Ingelheim US
- Trends & Insights | Boehringer Ingelheim US
- Mental Health | Boehringer Ingelheim US
- Across Cancer Types | Boehringer Ingelheim US
- Human Health | Boehringer Ingelheim US
- Patient Centricity | Boehringer Ingelheim US
- Veterinary Public Health | Boehringer Ingelheim US
- Where to find us | Boehringer Ingelheim US
- Animal Health | Boehringer Ingelheim US
- Lung Cancer | Boehringer Ingelheim US
- Chronic Kidney Disease | Boehringer Ingelheim US
- Pulmonary Fibrosis | Boehringer Ingelheim US
- Empowering Patients | Boehringer Ingelheim US
- Metabolic Diseases | Boehringer Ingelheim US
- COPD & Asthma | Boehringer Ingelheim US
- Diabetes | Boehringer Ingelheim US
- Retinal Diseases | Boehringer Ingelheim US
- Lung Diseases | Boehringer Ingelheim US
- Our Responsibility | Boehringer Ingelheim US
- Bronchiectasis | Boehringer Ingelheim US
- Scleroderma | Boehringer Ingelheim US
- Obesity | Boehringer Ingelheim US
- Heart Failure | Boehringer Ingelheim US
- Sustainable Development - Our Commitment | Boehringer Ingelheim US
- Ethics and Compliance | Boehringer Ingelheim US
- MORE HEALTH | Boehringer Ingelheim US
- Hypertension | Boehringer Ingelheim US
- Stroke | Boehringer Ingelheim US
- Atrial Fibrillation | Boehringer Ingelheim US
- Speak Up – Compliance Hotline | Boehringer Ingelheim US
- MORE POTENTIAL | Boehringer Ingelheim US
- Purchasing | Boehringer Ingelheim US
- Culture | Boehringer Ingelheim US
- Our Stories | Boehringer Ingelheim US
- Belonging | Boehringer Ingelheim US
- Sustainable Development | Boehringer Ingelheim US
- Press Releases | Boehringer Ingelheim US | Boehringer Ingelheim US
- Terms of Use | Boehringer Ingelheim US
- Animal Health Partnering Interests | Boehringer Ingelheim US
- Boehringer Ingelheim Cares Foundation US Privacy Statement | Boehringer Ingelheim US
- Explore our company | Boehringer Ingelheim US
- Animal Health Products | Boehringer Ingelheim US
- Spain | Boehringer Ingelheim US
- Get in touch | Boehringer Ingelheim US
- Press Material | Boehringer Ingelheim US
- China | Boehringer Ingelheim US
- Engineering & Facilities | Boehringer Ingelheim US
- Anna Race | Boehringer Ingelheim US
- Corporate Strategy & Consulting | Boehringer Ingelheim US
- Cookie Statement | Boehringer Ingelheim US
- Purpose Video IT | Boehringer Ingelheim US
- FAQ | Boehringer Ingelheim US
- Consumer Health Data Privacy Statement | Boehringer Ingelheim US
- US Privacy Statement | Boehringer Ingelheim US
- Search | Boehringer Ingelheim US
- How to Connect | Boehringer Ingelheim US
- Jessica Bürner | Boehringer Ingelheim US
- Accessibility Statement | Boehringer Ingelheim US
- See our Boehringer Ingelheim locations | Boehringer Ingelheim US
- Collaborative Opportunities | Boehringer Ingelheim US
- Search and apply | Boehringer Ingelheim US
- Partnering Interests | Boehringer Ingelheim US
- Connect with us | Boehringer Ingelheim US
- Our Working Culture | Boehringer Ingelheim US
- Our Focus: Cultural Framework | Boehringer Ingelheim US
- Commercial | Boehringer Ingelheim US
- Discover our careers | Boehringer Ingelheim US
- Medicine & Regulatory Affairs | Boehringer Ingelheim US
- US Careers | Boehringer Ingelheim US
- Perspectives | Boehringer Ingelheim US
- How to apply | Boehringer Ingelheim US
- Animal Health Partnering | Boehringer Ingelheim US
- Dr Paola Casarosa | Boehringer Ingelheim US
- Information Technology | Boehringer Ingelheim US
- Imprint | Boehringer Ingelheim US
- Manufacturing & Supply Chain | Boehringer Ingelheim US
- Total Rewards | Boehringer Ingelheim Careers | Boehringer Ingelheim US
- What our partners say | Boehringer Ingelheim US
- Ruminants | Boehringer Ingelheim US
- Partnership stories | Boehringer Ingelheim US
- Newsletter | Boehringer Ingelheim US
- Working together | Boehringer Ingelheim US
- Human Health Partnering | Boehringer Ingelheim US
- Swine | Boehringer Ingelheim US
- Partnering | Boehringer Ingelheim US
- Quality at Boehringer Ingelheim | Boehringer Ingelheim US
- Human Health Innovation | Boehringer Ingelheim US
- Poultry | Boehringer Ingelheim US
- Animal Health: Our Responsibility | Boehringer Ingelheim US
- Horses | Boehringer Ingelheim US
- Vaccines | Boehringer Ingelheim US
- Science Stories | Boehringer Ingelheim US
- Fostering Science | Boehringer Ingelheim US | Boehringer Ingelheim US
- Leadership | Boehringer Ingelheim US
- Parasiticides | Boehringer Ingelheim US
- The Research Process | Boehringer Ingelheim US
- About Us | Boehringer Ingelheim US
- Animal Health Innovation | Boehringer Ingelheim US
- Clinical Studies | Boehringer Ingelheim US
- Our Science Focus | Boehringer Ingelheim US
- Science & Innovation | Boehringer Ingelheim US
- Therapeutics | Boehringer Ingelheim US
- MORE GREEN | Boehringer Ingelheim US
- Contact Us | Boehringer Ingelheim US
- History | Boehringer Ingelheim US
- MASH | Boehringer Ingelheim US
- Who we are | Boehringer Ingelheim US
- Heart Diseases | Boehringer Ingelheim US
- Human Health Products | Boehringer Ingelheim US
- Media Overview | Boehringer Ingelheim US
- Boehringer Ingelheim - Life Forward | Boehringer Ingelheim US
- "To join Boehringer Ingelheim was the best ever decision" | Boehringer Ingelheim US
- Bridging vet care deserts amid New World screwworm | Boehringer Ingelheim US
- Innovation and Growth Drive First-Half 2026 Performance | Boehringer Ingelheim US
- Understanding brain metastasis risk in lung cancer | Boehringer Ingelheim US
- Biomarker testing and precision medicine in lung cancer | Boehringer Ingelheim US
- Boehringer Ingelheim Missouri Western State University Bio-Process Certificate Program | Boehringer Ingelheim US
- Boehringer advances three phase III trials in oncology | Boehringer Ingelheim US
- What is New World screwworm US Outbreak | Boehringer Ingelheim US
- A collective path to healthier futures | Boehringer Ingelheim US
- Partnering with Human Pharma at BIO International 2026 | Boehringer Ingelheim US
- Positive data from two Phase III SYNCHRONIZE obesity trials | Boehringer Ingelheim US
- Boehringer Presents Data Across Oncology Portfolio at ASCO | Boehringer Ingelheim US
- Stage Free: A Podcast for the Cancer Community | Boehringer Ingelheim US
- Results from Phase III SYNCHRONIZE-1 obesity trial | Boehringer Ingelheim US
- Atlanta Braves and Boehringer Ingelheim “Dogout” honors veterinarians - Photos | Boehringer Ingelheim US
- The Atlanta Braves and Boehringer Ingelheim unveil 2026 “Dogout” to honor veterinarians | Boehringer Ingelheim US
- Boehringer and Click Announce CT-155 Funding and Investment | Boehringer Ingelheim US
- Boehringer Ingelheim Athens Site Achieves Carbon Neutral Operations | Boehringer Ingelheim US
- NEJM publishes results for patients with HER2-mutant NSCLC | Boehringer Ingelheim US
- Boehringer Ingelheim launches STEM Innovation Lab in CT | Boehringer Ingelheim US
- Boehringer Ingelheim Reports 2025 Growth and Pipeline Progress | Boehringer Ingelheim US
- Parasites 101: How to help protect your pet from fleas, ticks & more | Boehringer Ingelheim US
- Submit your animal health partnering opportunity | Boehringer Ingelheim US
- Partnering and Innovation Outlook Animal Health 2026 | Boehringer Ingelheim US
- Wildlife Habitat Council certification at Ridgefield | Boehringer Ingelheim US
- Emergency Use Authorization to Help Protect Cattle Against New World Screwworm | Boehringer Ingelheim US
- Pitching for Partnerships in Animal Health | Boehringer Ingelheim US
- Advancing animal health with innovation and collaboration | Boehringer Ingelheim US
- Boehringer Ingelheim Expands Research and Development in Athens, Georgia | Boehringer Ingelheim US
- Strengthening Communities Through Animal Health: Boehringer Ingelheim Cares Foundation Provides Critical Medicine Donations | Boehringer Ingelheim US
- Boehringer Ingelheim Cares Foundation donates over two million doses of animal health medicines | Boehringer Ingelheim US
- Building tomorrow's leaders through STEM | Boehringer Ingelheim US
- Animal Health Partnering Contacts | Boehringer Ingelheim US
- FDA Approves Targeted Therapy for HER2-Mutant Advanced NSCLC | Boehringer Ingelheim US
- Management Systems | Boehringer Ingelheim US
- Raising Questions or Concerns | Boehringer Ingelheim US
- The Supplier Code of Conduct | Boehringer Ingelheim US
- The Realities of epNEC: A Rare and Aggressive Cancer | Boehringer Ingelheim US
- Boehringer licenses novel antibody for autoimmune diseases | Boehringer Ingelheim US
- Improving access to veterinary vaccines for shelter animals | Boehringer Ingelheim US
- Boehringer licenses autoimmune disease small molecule program | Boehringer Ingelheim US
- Biotherapeutics Discovery | Boehringer Ingelheim US
- Linda Clemons kicks off Boehringer Ingelheim’s CABLE Speaker Series | Boehringer Ingelheim US
- Going Beyond: Celebrating the essential role of veterinary technicians | Boehringer Ingelheim US
- Eye Health Research | Boehringer Ingelheim US
- BEST Program Welcomes Graduate Talent to Ridgefield | Boehringer Ingelheim US
- Advancing digital health through secure data collaboration | Boehringer Ingelheim US
- Boehringer launches swine vaccine with advanced protection against PCV2 | Boehringer Ingelheim US
- Computational Innovation | Boehringer Ingelheim US
- Boehringer celebrates next generation of biomedical researchers at 2025 Veterinary Scholars Symposium | Boehringer Ingelheim US
- Monarch magic: Ridgefield, CT pollinator event | Boehringer Ingelheim US
- Boehringer Ingelheim and LEO Pharma announce partnership | Boehringer Ingelheim US
- Partnering for Animal Health Innovation | Boehringer Ingelheim US
- Our power. Our planet. Our people: Promoting sustainable development excellence | Boehringer Ingelheim US
- Therapeutic Vaccines in Animal Health for Chronic Disease in Pets | Boehringer Ingelheim US
- An ongoing commitment to water stewardship: Fremont’s sustainable journey | Boehringer Ingelheim US
- Retinal health: All eyes on vision loss | Boehringer Ingelheim US
- Boehringer Cares shows commitment to next generation of innovators by welcoming students to our sites to participate in STEM Day | Boehringer Ingelheim US
- The Partner's Champion - Transactions and Alliance Management | Boehringer Ingelheim US
- The liver and its vital connection to our overall health | Boehringer Ingelheim US
- Interdisciplinary approach to CKM care | Boehringer Ingelheim US
- Hurricane help: Our unwavering support of storm victims | Boehringer Ingelheim US
- Where to meet us | Boehringer Ingelheim US
- U.S. FDA grants Breakthrough Therapy designation for MASH | Boehringer Ingelheim US
- Boehringer’s unique approach to innovation | Boehringer Ingelheim US
- Schizophrenia in real life: Stories of resilience and hope | Boehringer Ingelheim US
- Boehringer Ingelheim Subsidiaries and Affiliate Companies | Boehringer Ingelheim US
- Building lasting partnerships for a better future | Boehringer Ingelheim US
- PAP Resources | Boehringer Ingelheim US
- How to Apply | Boehringer Ingelheim US
- Advancing green chemistry for more sustainable medicines | Boehringer Ingelheim US
- Targeting HER2 in cancer | Boehringer Ingelheim US
- Translating Human Pharma Science into Animal Health Innovation | Boehringer Ingelheim US
- Improving Access to Clinical Trials | Boehringer Ingelheim US
- Results announced from EMPACT-MI phase III trial | Boehringer Ingelheim US
- Our evolved employer value proposition | Boehringer Ingelheim US
- Our evolved employer value proposition | Boehringer Ingelheim US
- Code of Conduct | Boehringer Ingelheim US
- Interview with Norbert Kraut: How cancer drives us forward | Boehringer Ingelheim US
- Ridgefield Research and Innovation | Boehringer Ingelheim US
- Our partners Bioveta | Boehringer Ingelheim US
- Poultry vaccine site in Georgia continues to reduce carbon emissions | Boehringer Ingelheim US
- A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters | Boehringer Ingelheim US
- FDA approved treatment option for adults with CKD | Boehringer Ingelheim US
- Six creative Connecticut students turn aspiring ideas into inventive innovation | Boehringer Ingelheim US
- Our Innovation Strategy | Boehringer Ingelheim US
- A day of giving back at Pegasus Therapeutic Riding | Boehringer Ingelheim US
- Confronting health disparities in clinical trials | Boehringer Ingelheim US
- Talking drug discovery with our U.S. research site head, Carine Boustany | Boehringer Ingelheim US
- The Importance of Drug Discovery | R&D | Boehringer Ingelheim US | Boehringer Ingelheim US
- Boehringer Cares Financial Contributions Program: Strengthening Communities | Boehringer Ingelheim US
- Our Businesses | Boehringer Ingelheim US
- Boehringer Cares Patient Assistance Portal | Boehringer Ingelheim US
- Rising Star Leads with Determination | Boehringer Ingelheim US | Boehringer Ingelheim US
- Company History | Corporate Profile | Boehringer Ingelheim US | Boehringer Ingelheim US
- History of our Logo | Corporate Profile | Boehringer Ingelheim US | Boehringer Ingelheim US
- 1885-1948: Innovative Beginnings | Boehringer Ingelheim US | Boehringer Ingelheim US
- BI Launches Bovikalc Dry for Dairy Cows | Boehringer Ingelheim US | Boehringer Ingelheim US
- Foot & Mouth Disease US Supply Vaccines | Boehringer Ingelheim US | Boehringer Ingelheim US
- Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH | Boehringer Ingelheim US
- Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic | Boehringer Ingelheim US
- Protecting a Way of Life in Haiti | Boehringer Ingelheim US | Boehringer Ingelheim US
- New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status | Boehringer Ingelheim US
- Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers | Boehringer Ingelheim US
- Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction | Boehringer Ingelheim US
- New Documentary Highlights Ranch’s Commitment to Cattle Health | Boehringer Ingelheim US
- Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US | Boehringer Ingelheim US
- Boehringer Ingelheim launches vaccine to protect poultry from three diseases | Boehringer Ingelheim US
- Clinical Trials | Boehringer Ingelheim US
- Innovation in Immunology | Human Health | Boehringer Ingelheim US | Boehringer Ingelheim US
- Innovation in CNS Disease Research | Boehringer Ingelheim US
- Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies | Boehringer Ingelheim US
- Innovation in Cardiovascular-Renal-Metabolic Disease Research | Boehringer Ingelheim US
- Boehringer Ingelheim’s Research and Development Postdoctoral Fellowship Program | Boehringer Ingelheim US
- Innovation in Oncology and Cancer Immunology | Boehringer Ingelheim US
- Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office | Boehringer Ingelheim US
- Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US | Boehringer Ingelheim US
- First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US | Boehringer Ingelheim US
- U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes | Boehringer Ingelheim US
- Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease | Boehringer Ingelheim US